Frontline Seed
For European Startups with Global Ambition
Frontline Seed helps ambitious B2B software businesses in Europe expand to the U.S. on their path to IPO
Accelerating your ambition
We move fast, invest early, and specialise in U.S. expansion.
Whether it’s at Pre-Product, Pre-Seed or Seed-stage – we aim to be the first institutional investor in the highest-potential B2B software businesses in Europe.
Beyond capital investment, our goal is to set each of our portfolio companies on the right path for Series A and eventually IPO, helping you launch across the U.S. along the way.
Where we Excel
Speed of execution
Our average time from first meeting to term sheet is 3 weeks. Our record is 3 days.
U.S. Expansion
Expert advice on how and when to enter the U.S. market
Further Funding
From pitch practice to deck assistance and, most importantly, network sharing
Personal support
We're the first port of call for founders' good news, bad news, and everything in between
Experts in U.S. Expansion
Raising your next round
We pride ourselves on supporting every step of future funding processes, helping founders secure the capital they need to fulfil their potential.
We offer support with preparing pitch decks and data rooms, making introductions to our extensive network of investors, and even helping to negotiate term sheets.
We have an especially strong track record helping portfolio companies raise their Series A; Frontline outperforms other European funds with a 75% Seed to Series A graduation rate (the average in Europe is just 15%).
The U.S. Playbook
The US Playbook outlines the key challenges founders will face entering the US market, and offers frameworks to overcome them — from choosing when and where to land, to attracting talent and managing teams across continents.
Learnings from 200+ Founders
We’ve explored which attributes early-stage founders really look for in their investors, and how these change depending on the founder profile.
Survey: What Founders Want
Exploring which attributes early-stage founders really look for in their investors, and how these change depending on the founder profile
CONQUERING THE US: 6 LESSONS FOR HEALTHTECHS
We provide six pearls of wisdom that every healthtech company should know before expanding State-side.
THE NEW (SYNTHETIC) DATA MOAT
A deep dive into the emerging market of synthetic data: What is synthetic data, how can we use it, and what opportunities does it offer?
